Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Merck
McKesson
Medtronic
Mallinckrodt

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,814,672

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,814,672
Title:Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi
Abstract: We disclose a composition comprising an echogenic liposome (ELIP) having an exterior surface, an interior surface, and at least one bilayer comprising at least one lipid selected from the group consisting of saturated phospholipids, unsaturated phospholipids, mixed phospholipids, and cholesterol, and a thrombolytic compound trapped by the ELIP. We also disclose a method of treating a medical condition in a patient characterized by a thrombus in the patient\'s vasculature, comprising administering to the patient the composition in an amount effective to reduce the size of the thrombus.
Inventor(s): Laing; Susan T. (Houston, TX), Huang; Shaoling (Houston, TX), McPherson; David D. (Houston, TX), Holland; Christy K. (Cincinnati, OH), Klegerman; Melvin E. (Houston, TX)
Assignee:
Application Number:12/044,189
Patent Claims:1. A composition, comprising: an intrinsically echogenic liposome (ELIP) having an exterior surface, an interior surface, and at least one bilayer comprising mannitol and at least one lipid selected from the group consisting of saturated phospholipids, unsaturated phospholipids, mixed phospholipids, and cholesterol, wherein the ELIP comprises from about 0 mole parts to about 90 mole parts DPPC, from about 0 mole parts to about 50 mole parts DOPC, from about 10 mole parts to about 50 mole parts DPPG, from about 0 mole parts to about 20 mole parts DPPE, from about 0 mole parts to about 90 mole parts egg PC, and from about 2 mole parts to about 15 mole parts cholesterol, wherein the total amount of DPPC, DOPC, DPPG, DPPE, egg PC, and cholesterol is 100 mole parts, a thrombolytic compound trapped by the ELIP, and tissue plasminogen activator (tPA) exposed on the exterior surface of the ELIP, wherein the tPA is the only active targeting molecule exposed on the exterior surface of the ELIP, and the enzymatic activity of the tPA exposed on the exterior surface of the ELIP is inhibited.

2. The composition of claim 1, wherein the enzymatic activity of the tPA exposed on the exterior surface of the ELIP is inhibited with D-phe-L-pro-L-arg-chloromethyl ketone (PPACK), and the tPA exposed on the exterior surface of the ELIP is conjugated to the ELIP by a thioether linkage.

3. The composition of claim 1, wherein the ELIP comprises about 46 mole parts DPPC, about 24 mole parts DOPC, about 24 mole parts DPPG, and about 6 mole parts cholesterol.

4. The composition of claim 1, wherein the thrombolytic compound is human tissue plasminogen activator (tPA).

5. The composition of claim 4, wherein the composition comprises from about 1 .mu.g to about 50 .mu.g entrapped tPA per 1 mg ELIP.

6. The composition of claim 1, further comprising a glycoprotein (GP) IIb/IIIa inhibitor selected from the group consisting of abciximab, eptifibatide, and tirofiban.

7. The composition of claim 1, wherein the ELIP comprises about 38 mole parts DPPC, about 24 mole parts DOPC, about 24 mole parts DPPG, about 8 mole parts DPPE, and about 6 mole parts cholesterol.

8. A method of treating a medical condition in a patient characterized by a thrombus in the patient's vasculature, comprising: administering to the patient, in an amount effective to reduce the size of the thrombus, a composition comprising an intrinsically echogenic liposome (ELIP) having an exterior surface, an interior surface, and at least one bilayer comprising mannitol and at least one lipid selected from the group consisting of saturated phospholipids, unsaturated phospholipids, mixed phospholipids, and cholesterol, wherein the ELIP comprises from about 0 mole parts to about 90 mole parts DPPC, from about 0 mole parts to about 50 mole parts DOPC, from about 10 mole parts to about 50 mole parts DPPG, from about 0 mole parts to about 20 mole parts DPPE, from about 0 mole parts to about 90 mole parts egg PC, and from about 2 mole parts to about 15 mole parts cholesterol, wherein the total amount of DPPC, DOPC, DPPG, DPPE, egg PC, and cholesterol is 100 mole parts; a thrombolytic compound trapped by the ELIP; and tissue plasminogen activator (tPA) exposed on the exterior surface of the ELIP, wherein the tPA is the only active targeting molecule exposed on the exterior surface of the ELIP and the enzymatic activity of the tPA exposed on the exterior surface of the ELIP is inhibited.

9. The method of claim 8, wherein the enzymatic activity of the tPA exposed on the exterior surface of the ELIP is inhibited with D-phe-L-pro-L-arg-chloromethyl ketone (PPACK), and the tPA exposed on the exterior surface of the ELIP is conjugated to the ELIP by a thioether linkage.

10. The method of claim 8, wherein the ELIP comprises about 46 mole parts DPPC, about 24 mole parts DOPC, about 24 mole parts DPPG, and about 6 mole parts cholesterol.

11. The method of claim 8, wherein the thrombolytic compound is human tissue plasminogen activator (tPA).

12. The method of claim 11, wherein the composition further comprises a glycoprotein (GP) IIb/IIIa inhibitor selected from the group consisting of abciximab, eptifibatide, and tirofiban.

13. The method of claim 8, wherein administering delivers to the patient from about 1 .mu.g of the thrombolytic compound per kg body weight to about 1 mg of the thrombolytic compound per kg body weight.

14. The method of claim 8, further comprising ultrasonic imaging of the thrombus.

15. The method of claim 8, further comprising applying ultrasonic energy to the ELIP and thrombus to enhance thrombolysis.

Details for Patent 9,814,672

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REOPRO abciximab INJECTABLE; INJECTION 103575 001 1994-12-22   Start Trial 2027-03-09 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Harvard Business School
AstraZeneca
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.